Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Sarcoma, Clear Cell × dostarlimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 14 Endometrial Neoplasms 14 Carcinoma, Non-Small-Cell Lung 9 Ovarian Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Neoplasm Metastasis 6 Uterine Cervical Neoplasms 5 Head and Neck Neoplasms 5 Melanoma 4 Colonic Neoplasms 4 Rectal Neoplasms 3 Pancreatic Neoplasms 3 Breast Neoplasms 3 Stomach Neoplasms 2 Osteosarcoma 2 Multiple Myeloma 2 Lung Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Neuroendocrine 2 Carcinoma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Turcot syndrome 1 Triple Negative Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Sarcoma, Clear Cell 1 Sarcoma 1

Interventions

Cyclophosphamide 4 Topotecan 3 Ifosfamide 3 Doxorubicin 3 seclidemstat 2 pazopanib 2 Biopsy 2 tebentafusp 1 selinexor 1 pembrolizumab 1 pegylated granulocyte colony-stimulating factor 1 fludarabine phosphate 1 fludarabine 1 dostarlimab 1 devimistat 1 cobimetinib 1 atezolizumab 1 Zoledronic Acid 1 X-Rays 1 Vemurafenib 1 Sunitinib 1 Specimen Handling 1 Sirolimus 1 Simvastatin 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Radiation 1 Proton Therapy 1 Nivolumab 1 Methotrexate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04274023 2024-02-01

ACCeSs

Italian Sarcoma Group

Phase 2 Terminated

Sarcoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡